OOIR: Observatory of International Research

Papers

(The H4-Index of Arthritis & Rheumatology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Reply	818
Minimal tofacitinib dose for maintenance in axial spondyloarthritis: real‐world data from a resource‐limited setting	305
Correction to “Novel Genetic Loci in Early‐Onset Gout Derived From Whole‐Genome Sequencing of an Adolescent Gout Cohort”	213
National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource, But with Limitations	167
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of ABBV‐154 in Adults With Glucocorticoid‐Dependent Polymyalgia Rheumatica: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Tr	155
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases	154
A Randomized, Double‐Blind, Placebo‐Controlled Trial of Abatacept for the Treatment of Relapsing, Nonsevere Granulomatosis With Polyangiitis	151
Contribution of Interleukin‐4–Induced Epithelial Cell Senescence to Glandular Fibrosis in IgG4‐Related Sialadenitis	136
Pregnancy Outcomes in Women With Psoriatic Arthritis in Relation to Presence and Timing of Antirheumatic Treatment	135
Role of Glutaminase 2 in Promoting CD4+ T Cell Production of Interleukin‐2 by Supporting Antioxidant Defense in Systemic Lupus Erythematosus	129
Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial	128
Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthr	127
Improvement in Disease Activity in Refractory Juvenile Dermatomyositis Following Abatacept Therapy	108
Endogenous Retroelement Activation is Implicated in Interferon‐α Production and Anti–Cyclic Citrullinated Peptide Autoantibody Generation in Early Rheumatoid Arthritis	104
Disturbed Spatial WNT Activation—A Potential Driver of the Reticularized Skin Phenotype in Systemic Sclerosis	102
Long‐Term Safety and Efficacy of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis	99
Identification of Shared and Asian‐Specific Loci for Systemic Lupus Erythematosus and Evidence for Roles of Type III Interferon Signaling and Lysosomal Function in the Disease: A	98
A methodologic problem and a conceptual issue related to the new 2022 antineutrophil cytoplasmic antibody–related vasculitis criteria sets: comment on criteria sets approved by the American College of	98
Classification Criteria for Axial Disease in Youth With Juvenile Spondyloarthritis	94
The Evolving Role of the Rheumatology Practitioner in the Care of Immunocompromised Patients in the COVID‐19 Era	93
No differences in myocardial perfusion between treatment‐naive, early rheumatoid arthritis patients and healthy controls	93
	90
Interleukin‐13 Receptor α1–Mediated Signaling Regulates Age‐Associated/Autoimmune B Cell Expansion and Lupus Pathogenesis	82
Sex Differences in B Cells From the Joints of Children With Oligoarticular Juvenile Idiopathic Arthritis	82
Clinical Connections	80

Gut Microbiome and Osteoarthritis: Insights From the Naturally Occurring Canine Model of Osteoarthritis	73
In This Issue	71
Targeting the Myddosome in Systemic Autoimmunity: Ready for Prime Time?	70
NLRP3 Attenuates Intraocular Inflammation by Inhibiting AIM2‐Mediated Pyroptosis Through the Phosphorylated Salt‐Inducible Kinase 1/Sterol Regulatory Element Binding T	69
At the Heart of Treating Kawasaki Disease: The Search for New Approaches to Prevent Coronary Artery Aneurysms	67
Assessing the Immune Cell Subset and Genetic Mutations in Patients With Palindromic Rheumatism Seronegative for Rheumatoid Factor and Anti–Cyclic Citrullinated Peptide	63
Using Mice to Model Human Osteoarthritis: Age, Biologic Sex, and Pain Matter	62
Clinical Images: Rice bodies in pseudogout	61
Reply	60
Association of change in metabolic syndrome status with altered risk of incident gout: comment on the article by Eun et al	59
In This Issue	59
The Devil Is in the Detail: Clinical Practice Guideline for the Optimal Timing of Elective Hip or Knee Arthroplasty	58
Clinical Connections	56
CCL19‐Positive Lymph Node Stromal Cells Govern the Onset of Inflammatory Arthritis via Tropomyosin Receptor Kinase	56
Systemic lupus erythematosus and atherosclerosis progression risk: comment on the article by Papazoglou et al.	55
	54
Possible confounding factors explaining data on heart failure risk in patients with polymyositis/dermatomyositis: comment on the article by Lin et al	54
Knee Alignment Correction by High Tibial Osteotomy Reduces Symptoms and Synovial Inflammation in Knee Osteoarthritis Accompanied by Macrophage Phenotypic Change From M1 to M2	53
Seronegative palindromic rheumatism: what are we talking about? Comment on the article by Yang et al	53
Higher alcohol consumption was associated with greater incidence of total hip replacement due to hip osteoarthritis in a dose‐dependent manner in women: comment on the article by Marchand et al	53
Derivation of a Multivariable Psoriatic Arthritis Risk Estimation Tool (PRESTO): A Step Towards Prevention	52
Incidence, Prevalence, and Mortality of Lupus Nephritis: A Population‐Based Study Over Four Decades Using the Lupus Midwest Network	51
Phase III/IV, Randomized, Fifty‐Two–Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus	50
The 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria	50
The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial	50